PATENT CLAIM ANALYSIS

Application Number: 16160840
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["514", "157000"]

Abstract:
This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions.

Claim (Index 4):
The method of  claim 2 , wherein X 3  is \u2014SO 2 CF 3  or \u2014NO 2 , and\n R 8  is wherein X 4  is \u2014OH or \u2014COOH.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 97.0
- Lexical Diversity: 1.5567
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15467129', '15647688', '14833041', '16054667', '15956613']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.653002972548617
- 35 USC 102 Novelty (BERT): 0.5329439713708077
- Combined Prediction Score: 0.640997072430836
- Mean Citation Score: 269.93830800000006
- Max Citation Score: 304.62137
- Similarity Product: 181.9051134705425

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test